diphtheria, tetanus, pertussis & Hib vaccine — Competitive Intelligence Brief

diphtheria, tetanus, pertussis & Hib vaccine (diphtheria, tetanus, pertussis & Hib vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

phase 3 vaccine Immunology Biologic

Target snapshot

diphtheria, tetanus, pertussis & Hib vaccine (diphtheria, tetanus, pertussis & Hib vaccine) — GlaxoSmithKline. This vaccine stimulates the body's immune response to produce antibodies against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
diphtheria, tetanus, pertussis & Hib vaccine TARGET	diphtheria, tetanus, pertussis & Hib vaccine	GlaxoSmithKline	phase 3	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
4CMenb	4CMenb	CHU de Quebec-Universite Laval	marketed	Conjugate vaccine	Neisseria meningitidis serogroup B polysaccharide capsule
Boostrix™-US formulation	Boostrix™-US formulation	GlaxoSmithKline	marketed	Inactivated bacterial vaccine
sIPV batch 1	sIPV batch 1	Institute of Medical Biology, Chinese Academy of Medical Sciences	marketed	Inactivated viral vaccine	Poliovirus types 1, 2, and 3
sIPV+DTaP+MMR	sIPV+DTaP+MMR	China National Biotec Group Company Limited	marketed	Combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class